Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression

Immunotherapy is an important and established treatment option for patients with advanced melanoma. Initial anti-PD1 trials arbitrarily defined a two-year treatment duration, but a shorter treatment duration may be appropriate. In this study, we retrospectively assessed 70 patients who stopped anti-...

Full description

Bibliographic Details
Main Authors: Lydia Warburton, Leslie Calapre, Michelle R. Pereira, Anna Reid, Cleo Robinson, Benhur Amanuel, Mel Ziman, Michael Millward, Elin Gray
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
melanoma
immune checkpoint inhibitors
anti-PD1
complete response
therapy cessation
ctDNA
Online Access:https://www.mdpi.com/2072-6694/12/11/3486

Internet

https://www.mdpi.com/2072-6694/12/11/3486

Similar Items